Harmony Biosciences to Present New Data on EPX-100 for Dravet Syndrome Next Week at American Epilepsy Society Annual Meeting.
ByAinvest
Wednesday, Dec 3, 2025 5:04 am ET1min read
HRMY--
Harmony Biosciences will present new data from its ongoing ARGUS trial on EPX-100 for Dravet syndrome at the American Epilepsy Society Annual Meeting. The trial includes a 4-week observational period, a 16-week double-blind period, and an open-label extension period. EPX-100 is an adjunctive therapy being evaluated for efficacy and safety in children and adults with Dravet syndrome. The company expects topline data in 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet